NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Telomir Pharmaceuticals' Positive Telomir-1 Results in Triple-Negative Breast Cancer Study
TL;DR
Telomir Pharmaceuticals' Telomir-1 shows potential to outperform paclitaxel in aggressive triple-negative breast cancer models, offering a promising new therapeutic advantage.
Telomir-1 demonstrated statistically significant tumor growth reduction in zebrafish xenograft models, both as monotherapy and in combination with paclitaxel, through epigenetic and metabolic targeting.
This breakthrough could lead to more effective treatments for aggressive cancers, potentially improving survival rates and quality of life for patients worldwide.
A preclinical drug targeting epigenetic mechanisms shows surprising effectiveness against aggressive breast cancer in zebrafish models, even outperforming standard chemotherapy in some cases.
Found this article helpful?
Share it with your network and spread the knowledge!
Telomir Pharmaceuticals announced positive results from an efficacy study evaluating its lead drug candidate Telomir-1 in zebrafish tumor xenograft models of triple-negative breast cancer, showing statistically significant reductions in tumor growth and metastatic dissemination.
Telomir-1 (also referred to as Zn-Telomir) is a small-molecule therapeutic designed to target epigenetic and metabolic drivers of disease, specifically addressing root epigenetic mechanisms underlying cancer, aging, and degenerative disease.
In an aggressive TNBC model with limited responsiveness to paclitaxel, Telomir-1 demonstrated statistically significant reductions in primary tumor growth and metastatic dissemination. In another aggressive TNBC model where paclitaxel showed activity, Telomir-1 achieved comparable tumor growth reduction as a monotherapy and produced greater inhibition when combined with paclitaxel than either agent alone.
The study was conducted in collaboration with BioReperia using its ZTX(R) ONCOLEADS platform, which utilizes zebrafish tumor xenograft models for cancer research.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company, meaning its drug candidates are still in the research and development phase before human clinical trials.
In preclinical studies, Telomir-1 has demonstrated activity involving modulation of DNA and histone methylation, restoration of redox balance, and normalization of cellular function.
The latest news and updates relating to TELO are available in the company's newsroom at https://ibn.fm/TELO, and the full press release can be viewed at https://ibn.fm/JwPXi.
MissionIR is a specialized communications platform that assists IR firms with syndicated content to enhance the visibility of private and public companies within the investment community, providing services including wire solutions, editorial syndication, press release enhancement, social media distribution, and corporate communications solutions.
This study is significant because it shows Telomir-1's effectiveness in aggressive TNBC models, including those with limited responsiveness to paclitaxel, suggesting potential as a new therapeutic option for this challenging cancer type.
Curated from InvestorBrandNetwork (IBN)
